Background: Luminal breast cancer is a highly endocrine responsive disease. However, the therapeutic benefit of chemotherapy (CT) in this population is not fully characterized. This study investigates the value of CT and hormone therapy (HT) in luminal breast cancer patients in the neoadjuvant setting. Results: Ninety-five patients were randomized (47 CT, 48 HT). The clinical response rate was 66% for CT and 48% for HT (P = 0.075). We performed an unplanned analysis based on Ki67 levels (cut-off of 10%). Similar clinical response was seen between arms in patients with low Ki67 (CT: 63%, HT: 58%; P = 0.74); patients with high Ki67 had a better response with CT (67 versus 42%; P = 0.075). Grade 3/4 toxicity was more frequent with CT.
introduction
The bases of knowledge allowing the development of new prognostic and predictive classifications of breast cancer were established in the past decade. One of the most widely studied classifications was proposed by the Perou group, which discriminates at least five intrinsic subtypes: luminal A, luminal B, HER2-enriched, basal-like, and normal-like [1] [2] [3] [4] [5] . The luminal subtype, which is broadly equivalent to the classical estrogen receptor (ER)-and/or progesterone receptor (PgR)-positive tumors assessed by immunohistochemistry (IHC), is characterized at the gene expression level by having a group of genes related to the ER, in addition to others such as GATA3, X-box protein 1, trefoil factor 3, FOXA 1, and LIV 1 [6, 7] . This luminal group is subdivided into the luminal A and luminal B subtypes [2] . The main difference between them is the expression of genes related to cell proliferation, such as the E2F regulatory gene [8, 9] .
The neoadjuvant treatment of breast cancer either with CT or with HT has been used to increase the number of patients amenable to conservative surgery. More recently, it has also been used for purely research purposes as it allows for a quantifiable assessment of in vivo sensitivity to the different types of treatment [10] .
Neoadjuvant CT is highly effective, with a clinical response rate ranging from 50% to 90%, although with a much lower pathological complete response ( pCR) rate ranging from 2% to 27% [11] . The CT-induced pCR has been considered a surrogate marker for disease-free and overall survival [12, 13] . The ER status is the most commonly recorded predictor of the efficacy to CT. At least 11 studies using different CT regimens have reported greater pCR rates in ER-negative tumors than in ER-positive ones [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . The HER2-enriched or basal genomic subtypes have recently been reported to be the predictors of higher pCR rates when compared with the luminal subtype [25, 26] .
Despite the strong biological rational to use neoadjuvant HT in luminal patients, this approach has not been widely studied and its use has been limited to elderly or fragile patients. The response rate ranges from 35% to 70%, though with low pCR rates of <5% [27] . The biological meaning of pCR in patients treated with HT is unknown. Hormonal receptor-positive (HR+) patients have a better long-term prognosis regardless of the pathological status at surgery [19, 21, 28] , which invalidates pCR as a robust surrogate marker in the hormone-responsive population.
Since CT achieves a very low pCR rate in HR+/HER2− patients (which are presumably within the luminal phenotype), and HT is a potentially good option in this patient subgroup, we designed a phase-II randomized study (GEICAM/2006-03) to evaluate CT and HT as neoadjuvant treatment of patients with luminal breast cancer.
patients and methods

eligibility criteria
Patients aged >18 years with histologically confirmed (by surgical or core biopsy) ER-positive (Allred 3-8), PgR-positive, HER2-negative, and cytokeratin 8/18-positive breast cancer were included. The tumor size had to be >2 cm, or less if there was axillary involvement ( pathologically confirmed). Patients were required to have Eastern Cooperative Oncology Group (ECOG) performance status ≤1, normal cardiac function, and adequate bone marrow, liver, and renal functions. Patients were excluded if they undergone treatment of the present disease, previous anthracycline and/or taxane administration, have concurrent treatment with corticosteroids, selective ER modulators or hormonal replacement therapy, had inflammatory, bilateral invasive, or metastatic breast cancer or if they had any other severe or uncontrolled systemic disease. Adequate contraception and a negative pregnancy tests were required for women of child-bearing potential. Patients with a previous history of cancer other than skin (no-melanoma), or cervix tumors adequately treated and other cancers treated more than 10 years prior to the study entry, were also excluded.
study design and treatment plan
This was a multicenter, open label, randomized, phase-II trial. All eligible patients were randomly assigned, in a 1:1 ratio, to receive neoadjuvant CT (standard arm) or HT (experimental arm) in blocks of eight. Randomization was centralized at the GEICAM headquarters. Patients were stratified according to institution, tumor size (<1 versus 1-2 versus 2-5 versus ≥ 5 cm), histological grade (I versus II versus III), and axillary status (N0 versus N+).
CT consisted of epirubicin 90 mg/m 2 plus cyclophosphamide 600 mg/m 2 both administered intravenously (i.v.) on day 1 every 21 days, for four cycles followed by docetaxel 100 mg/m 2 administered i.v. on day 1 every 21 days for four cycles. HT consisted of oral exemestane 25 mg daily for 24 weeks (same duration than CT). Premenopausal patients were also receiving goserelin 3.6 mg subcutaneously every 28 days for six doses. After neoadjuvant treatment, patients underwent mastectomy or conservative surgery plus axillary lymph node dissection (unless previous negative sentinel lymph node biopsy). Postoperative treatment was left under the investigator's criteria ( Figure 1 ). This trial was approved by the local Ethical Review Boards and the Spanish Ministry of Health, and registered in ClinicalTrials.Gov with the number NCT00432172. The trial was conducted in compliance with Good Clinical Practices and the tenets of the Declaration of Helsinki. All patients provided written informed consent before entering the study.
assessments and end points
The primary end point of the study was the clinical response rate. Secondary end points included safety, pCR rates, breast conservative surgery rate, and axillary node status at the time of surgery. original articles
Annals of Oncology
Before study entry, all patients underwent a breast and axillary disease assessment by magnetic resonance imaging (MRI). In addition, patients had undergone ECOG performance status evaluation, surgical or core biopsy, complete blood cell count, serum chemistry, electrocardiogram (ECG) and left ventricular ejection fraction measurement (if abnormal ECG).
The clinical response was evaluated according to the RECIST criteria [29] after 12 weeks and after study treatment using MRI. The pCR was assessed at surgery following the Miller and Payne criteria [30] . Adverse events were graded following the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 3.0 [31] . The worst grade for each patient was reported.
tumor tissue assessment
The ER, PgR, Ki67, and cytokeratin 8/18 (CK8/18) status was assessed by IHC in a central laboratory using Clone 1D5 (ER), Clone PGR 636 (PR), Clone 5D3 (CK8/18), and Clone MIB 1 (Ki67) (DakoCytomation, Glostrup, Denmark). HER-2 was evaluated by IHQ using HercepTest™ (DakoCytomation) and FISH (in case of IHC 2+) using PathVysion kit (Abbott Park, IL, USA).
KI67 analysis was not preplanned and was performed after the study completion.
statistical methods
A randomized, phase-II design was chosen not to enable the comparison of the efficacy of the two arms, but to explore whether the HT efficacy precluded a comparison with CT in a formal randomized, phase-III trial.
The sample size was calculated for the experimental arm using the twostage Simon method based on the primary study objective, clinical response. The sample size was based on a null hypothesis (H0) of clinical response <39% and alternative hypothesis (H1) of clinical response ≥60%. Assuming an alpha error of 0.05 and a test power of 80%, 45 assessable patients were required to be recruited in this arm. Fourteen patients were to be included in the first stage, if at least six responses were seen, 31 additional patients were to be included in the second stage up to a total of 45 evaluable patients. No minimum response criteria were proposed for CT as it was considered to be the gold standard.
The primary end point (clinical response) was analyzed in an intention to treat basis. The number and proportion of clinical responses in each treatment arm and their two-sided 95% confidence intervals were performed for the best overall response analysis. For hypothesis generation, exploratory analyses were conducted to compare the clinical response and adverse events between treatment arms using the χ 2 test.
results
patient characteristics
Between March 2007 and December 2008, 95 patients from 15 participating centers were included and randomized (47 patients to CT and 48 to HT). No statistically significant differences were seen in the patient characteristics between the treatment arms. The median age was 51 years (range: 32-74 years). More than half of the patients were premenopausal, 81% had a histological diagnosis of ductal carcinoma and 23, 60, and 17% had histological grade I, II, and III, respectively. The median tumor size measured by MRI was 4 cm (range: 0.8-10) with 74% of patients having T2 tumors and 55% negative axillary lymph nodes. Seventy-five percent of patients had an ER Allred score of 7-8. Ki67 was evaluated in 91 patients, 42% of them had tumors with Ki67 ≤10% (see Table 1 ). Figure 2 shows the consort study flowchart. Four patients (two per treatment arm) withdrew consent and never received treatment, thus were not considered assessable for safety. Nine patients, four and five in the CT and HT arms, respectively, discontinued treatment early. Reasons for the discontinuation were toxicity in six patients, disease progression in two patients (both in the HT arm) and one due to a different reason. Thus, 82 patients, 41 in each arm, completed the treatment as planned.
efficacy
The clinical response rate was 66% (95% CI: 52.5-79.5%) with CT and 48% (95% CI: 33.8-62%) with HT, in an exploratory analysis the P-value was 0.075. Complete clinical remission rates achieved with CT and HT were 13% and 6%, respectively. Four patients progressed with HT and one with CT (either while on treatment or at the end of it), (supplementary Table S1 , available at Annals of Oncology online).
Exploratory unplanned subgroup analyses were performed. A significant benefit of CT over HT was seen in premenopausal women, with response rates of 75% and 44%, respectively (P = 0.027), what was not observed in postmenopausal patients, with 57% for CT and 52% for HT (P = 0.78). Patients with the ER Allred score of 7-8 responded better to CT (68% and 41%, respectively, P = 0.026). No differences were seen in the response rate when analyzed by the tumor size, histological grade, or axillary lymph node status ( Table 2 ). An unplanned analysis showed an increase in the response rate with CT, almost reaching the statistical significance, in patients with Ki67 > 10%: 67% for CT and 42% for HT, P = 0.075. However, patients with Ki67 ≤ 10% seemed to have similar efficacy, with response rates of 63% and 58% for CT and HT, respectively, P = 0.74 ( Table 2) .
The pCR in both breast and axilla was very low, one patient with CT and none with HT. No significant differences were found in the rate of breast conservative surgery, 47% with CT and 56% with HT (P = 0.2369); or in the axillary lymph-node status after treatment, 36% and 29% with negative nodes with CT and HT, respectively (P = 0.6084).
safety
CT was more toxic than HT. Overall, 47% of patients given CT had grade 3-4 toxicity (excluding amenorrhea), compared with 9% of patients receiving HT; these differences were statistically significant (P < 0.001), (supplementary Table S2 , available at Annals of Oncology online). Patients receiving CT experienced more gastrointestinal toxicity, leukopenia, and neutropenia, with a febrile neutropenia rate of 7%. Neoadjuvant treatment has traditionally been used in breast cancer to increase the conservative surgery rates. More recently, it has also been used as a clinical model to quickly investigate the efficacy of new drugs or combinations [10] . The vast majority of studies in this field have been conducted with CT, providing a great amount of knowledge about this treatment modality. The presence of hormone receptors, especially ER, is a clear positive predictor of efficacy of the neoadjuvant HT [27, 32] and has been raised as a negative predictor of the efficacy of CT [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . These findings are consistent with the indirect data, suggesting that ER-positive patients show a lower sensitivity to cytotoxic drugs in the adjuvant treatment, as derived from the lower impact that CT is having on their DFS [33] [34] [35] [36] . Similar results have been seen using genomic platforms that identify luminal breast cancer subtypes [25, 26] .
These data suggest that CT is less effective in the genomically and immunohistochemically defined (ER+/HER2−) luminal subtype when compared with the HER2-enriched and basal-like subtypes.
However, there is a lack of robust data about the differential efficacy of CT versus HT in this luminal subpopulation. The only available evidence comes from a phase-II, randomized study where 239 patients with ER+ and/or PR+ tumors were randomized to CT with four cycles of anthracyclines and taxanes for 12 weeks, or HT with anastrozole or exemestane for 3 months. There were no differences, neither in the clinical nor in the pathological response, between the treatment arms in this study [37] . It should be noted that HER2 was not measured in this study, and that the response rate achieved in the HT arm was markedly higher than usually reported in randomized studies using neoadjuvant HT [32] .
The GEICAM/2006-03 study showed that in a highly hormone-responsive population (defined by IHC as ER+, PR+, HER2−, and CK 8/18+), CT achieved a greater clinical response rate than HT (66% versus 48%), almost reaching statistical significance (P = 0.075). Such a difference was even higher in patients with a high proliferation rate (Ki67 > 10%), 67% versus 42%, P = 0.075. In contrast, patients with a low proliferation rate (Ki67 ≤ 10%) had a similar response rate in both treatment arms (63% versus 58%, P = 0.74).
These data suggest that in highly hormone-responsive population, the proliferation rate could be the biological marker determining the differential efficacy between CT and HT. Previous data suggest that the luminal subtype (defined as ER+, HER2− by IHC) may be subdivided between luminal A and luminal B based on Ki67 [38] ; the cut-off used in this trial was 13.25%, similar to the 10% used by us. Our data suggest that CT appears to be more effective than HT for the luminal B patients, but both strategies seem to have a similar efficacy in the luminal A subtype, though HT could potentially be sufficient for those patients, as mentioned already by other authors [39] . Recent available data support this hypothesis; the cell proliferation module AURKA (consisting of its prototype gene, AURKA, and other related genes) was studied in almost 3000 breast cancer patients. ER− and HER2+ populations had a high expression index of the AURKA genes, i.e. they had a high proliferation index that could be the origin of their poor prognosis. However, what is more interesting is that the ER + tumors had a wider range of values in the expression of proliferation genes, grouping them into two subpopulations: (i) a group with a low proliferation index and good prognosis (presumably the luminal A subtype) and (ii) a high proliferation index and poorer prognosis (presumably the luminal B subtype). The ER+ group with low expression levels of proliferation genes had a significantly longer disease-free survival compared with the other three groups, and was speculated to be the group in which CT would have little or no value. It should be noted that these studies also suggest that, despite the importance of the biological factors mentioned, strictly anatomical parameters such as tumor size and number of positive axillary lymph nodes continue to have a prognostic value [40, 41] .
In our study premenopausal patients had a higher response with CT than with HT (75 versus 44%); this difference was not seen in the postmenopausal population. A possible explanation can be the length that takes the combination of AI and LHRH agonists to induce estradiol suppression (about 4 weeks) [42, 43] .
In contrast to what we would expect, in the GEICAM/ 2006-03 study CT also achieved a higher response rate than HT in patients with a higher ER Allred score (68 versus 41%). This is probably related to the fact that 61% of patients with an Allred score of 7-8 had Ki67 >10%.
For our group, this is a hypothesis-generating study. On the one hand, our data suggest that patients with ER+, PR+, and HER2− breast cancer and low proliferation index ( presumably the luminal A subtype) could potentially avoid the CT use in the adjuvant setting; though it need to be tested in a phase III trial comparing CT plus HT versus HT alone in this patient population. On the other hand, endocrine responsive patients with high proliferation index ( presumably the luminal B subtype) should be considered to receive CT as part of their adjuvant treatment plan.
acknowledgements
